 BOSTON and ROCKVILLE, Md., Feb. 03, 2021 GLOBE NEWSWIRE -- Sensei Biotherapeutics, Inc., a clinical-stage immunotherapy company focused on the discovery and development of next generation therapeutics for cancer, today announced the pricing of its upsized initial public offering of 7,000,052 shares of common stock at a public offering price of 19.00 per share. The gross proceeds to Sensei from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Sensei, are expected to be approximately 133.0 million. All of the shares are being offered by Sensei and are expected to begin trading on The Nasdaq Global Market on February 4, 2021 under the ticker symbol SNSE. In addition, Sensei has granted the underwriters a 30-day option to purchase up to an additional 1,050,007 shares of common stock at the initial public offering price, less underwriting discounts and commissions. The offering is expected to close on February 8, 2021 subject to the satisfaction of customary closing conditions. 